Domov › Nemalicelični pljučni rak › Kalifornija › San Francisco
Klinične študije za Nemalicelični pljučni rak v San Francisco, CA
36 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v San Francisco in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study of ZW251 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- UCSF Comprehensive Cancer Center, San Francisco
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Vključevanje udeležencevFaza 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Vključevanje udeležencevFaza 3
- UCSF Medical Center at Mission Bay ( Site 0178), San Francisco
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Vključevanje udeležencevFaza 3
- Kaiser Permanente-San Francisco, San Francisco
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Vključevanje udeležencevFaza 3
- San Francisco Oncology Associates ( Site 0066), San Francisco
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 2
- UCSF Zuckerberg San Francisco General Hospital, San Francisco
Intratumoral N17350 in Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of California, San Francisco, San Francisco
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Vključevanje udeležencevFaza 3
- Research Site, San Francisco
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Vključevanje udeležencevFaza 3
- UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Vključevanje udeležencevFaza 3
- University of California San Francisco, San Francisco
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Vključevanje udeležencevFaza 1/2
- University of California, San Francisco (UCSF), San Francisco
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Vključevanje udeležencevFaza 2/3
- San Francisco Veterans Affairs Medical Center, San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology, San Francisco
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Vključevanje udeležencevFaza 3
- California Pacific Medical Center, San Francisco
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 1
- University of California San Francisco, San Francisco
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Vključevanje udeležencevFaza 1
- University of California San Francisco, San Francisco
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Vključevanje udeležencevFaza 1/2
- University of California San Francisco, San Francisco
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Vključevanje udeležencevFaza 3
- UCSF Medical Center-Mission Bay, San Francisco
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
Vključevanje udeležencevFaza 2
- University of California San Francisco, San Francisco
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Vključevanje udeležencevFaza 1/2
- UCSF Medical Center - Mission Bay, San Francisco
Biomarkers for Risk Stratification in Lung Cancer
Vključevanje udeležencevOpazovalna študija
- Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco
- San Francisco VA Medical Center, San Francisco
- University of California, San Francisco, San Francisco
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Vključevanje udeležencevFaza 1
- University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- California Pacific Medical Center-Pacific Campus, San Francisco
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2/3
- Kaiser Permanente-San Francisco, San Francisco
- Veterans Affairs Medical Center - San Francisco, San Francisco
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Vključevanje udeležencevFaza 2
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Vključevanje udeležencev
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- UCSF Medical Center at Mission Bay, San Francisco
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Vključevanje udeležencevFaza 1/2
- University of California at San Francisco, San Francisco
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Vključevanje udeležencevFaza 1/2
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Vključevanje udeležencevOpazovalna študija
- Kaiser Permanente-San Francisco, San Francisco
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Vključevanje udeležencevFaza 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
Vključevanje udeležencevFaza 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
Vključevanje udeležencevOpazovalna študija
- Curebase, San Francisco
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Vključevanje udeležencevFaza 2
- University of California, San Francisco (UCSF), San Francisco
Študije za Nemalicelični pljučni rak v drugih mestih
- Houston, TX145 študij
- New York City, NY121 študij
- Arlington, VA104 študij
- Nashville, TN97 študij
- Boston, MA90 študij
- Los Angeles, CA87 študij
- St. Louis, MO73 študij
- Chicago, IL61 študij
- Baltimore, MD60 študij
- San Antonio, TX59 študij
- Columbus, OH57 študij
- Washington, DC55 študij
Druge študije v San Francisco
- Rak prostate45 študij
- Rak dojke43 študij
- Rak (vse vrste)35 študij
- Srčno popuščanje29 študij
- Metastatski rak28 študij
- Rak pljuč22 študij
- Melanom22 študij
- Rak trebušne slinavke20 študij
- Rak jajčnikov19 študij
- Kolorektalni rak18 študij
- Srčno-žilne bolezni18 študij
- Glioblastom17 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.